SSGJ-705

N/A

Report date: 2025/06/12 17:09:01

Base Information

Drug NameSSGJ-705

Drug Alias NameSSGJ-705705

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsProgrammed cell death protein 1 blockers

TargetsReceptor protein-tyrosine kinase erbB-2Programmed cell death protein 1

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd

Inactive CompaniesShenyang Sunshine Pharmaceutical Co Ltd

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A